Furthermore, GravityFit will be set to commercialise
a range of smart functioning training garments for athletes and astronauts, which aim to stabilise and strengthen spine and joints, reduce the risk of injury and improve performance.
CANbridge also has exclusive rights to develop and commercialise
Puma biotechnology's Nerlynx (neratinib) in China, Taiwan, Hong Kong and Macao (collectively, greater China); a license with Apogenix to develop and commercialise
APG101 in greater China; a license (ex-North America) to develop and commercialize AVEO Oncology's ErbB3 inhibitory antibody candidate AV203 and an agreement with EUSA Pharma to commercialise
Caphosol for the prevention and treatment of oral mucositis caused by cancer treatments, for which it has received approval in China.
Under the terms of the agreement, Mylan will commercialise
Lupin's proposed etanercept biosimilar in Europe, Australia, New Zealand, Latin America, Africa and most markets throughout Asia.
United States-based Mylan has acquired an exclusive license to commercialise
a biosimilar to Humira (adalimumab), developed by Fujifilm Kyowa Kirin Biologics, in Europe, it was reported yesterday.
The terms of the agreement give Zeria the exclusive right to develop and commercialise
Veltassa in Japan once marketing authorisation has been granted.
M2 PHARMA-April 19, 2018-ArQule Licenses Basilea to Develop and Commercialise
It was reported yesterday that the contract has been signed to develop and commercialise
products featuring KP-470, an investigational compound for the topical treatment of psoriasis.
M2 PHARMA-April 13, 2018-Mylan acquires exclusive license to commercialise
biosimilar to Humira
It is reported today that the contract has been signed for the rights to develop and commercialise
the vTv's GLP-1r agonist program in China and other Pacific Rim countries.
Under the terms of the agreement, the two companies will work together to develop and commercialise
Lynparza, both as a monotherapy and as a combination treatment with other potential medicines.
Swiss pharmaceutical company Ewopharma revealed on Thursday the completion of the acquisition of the commercialise
rights for several products from Eisai Co Ltd (TYO:4523) in 11 countries in Central and Eastern Europe (CEE).
M2 PHARMA-February 14, 2018-Medison Pharma to Commercialise
Nerlynx (neratinib) in Israel